All Companies

BMYCongressional Stock Trades

Bristol-Myers Squibb Co.

Pharmaceutical Preparations

Congressional stock trades in Bristol-Myers Squibb Co. (BMY) from House and Senate STOCK Act filings. See which members of Congress bought or sold, disclosed amounts, and filing dates.

Total Trades

17

Politicians Trading

10

Last Traded

Jun 16, 2026

Trading History

PoliticianNotifiedTradedTypeAmountChange
Alan ArmstrongRJul 21, 2026Mar 27, 2026Buy$1,001 - $15,000+5.42%
Ro KhannaDJun 9, 2026May 15, 2026Buy$1,001 - $15,000+8.26%
Gilbert Ray Cisneros, Jr.DJan 12, 2026Dec 19, 2025Buy$1,001 - $15,000+13.88%
Gilbert Ray Cisneros, Jr.DDec 15, 2025Nov 12, 2025Buy$1,001 - $15,000+25.73%
Julie JohnsonDFeb 12, 2025Jan 15, 2025Buy$1,001 - $15,000+10.37%

Price History

About Bristol-Myers Squibb Co.

Bristol Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Bristol derives close to 70% of total sales from the US, showing a higher dependence on the US market than most of its peer group.

FAQ

10 members of Congress have disclosed 17 trades in Bristol-Myers Squibb Co. (BMY). Most active: Julie Johnson (5), Gilbert Ray Cisneros, Jr. (3), Ro Khanna (2).

Across all disclosures, members of Congress reported 5 purchases and 12 sales of Bristol-Myers Squibb Co. (BMY). The most recent trade was on Jun 16, 2026.

Ro Khanna disclosed buying Bristol-Myers Squibb Co. (BMY) on May 15, 2026, valued at $1,001 - $15,000.

Ro Khanna disclosed selling Bristol-Myers Squibb Co. (BMY) on Jun 16, 2026, valued at $1,001 - $15,000.

From House and Senate periodic transaction reports filed under the STOCK Act. Members of Congress must disclose trades within 45 days, and amounts are reported as ranges, not exact values.